U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998.

Cover of Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline

Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline.

Show details



Niacin functions as a cosubstrate or coenzyme for the transfer of the hydride ion with numerous dehydrogenases. The primary criterion used to estimate the Recommended Dietary Allowance (RDA) for niacin is the urinary excretion of niacin metabolites. No adjustment is made for bioavailability, but the requirement is expressed in niacin equivalents (NEs), allowing for some conversion of the amino acid tryptophan to niacin. The RDA for adults is 16 mg/day of NEs for men and 14 mg/day of NEs for women. Recently, the median intake of preformed niacin from food in the United States was approximately 28 mg for men and 18 mg for women, and the ninety-fifth percentile of intake from both food and supplements was 40 to 70 mg of NEs, depending on age. In two Canadian populations the median intake of preformed niacin was approximately 41 mg/day for men and 28 mg/day for women. The Tolerable Upper Intake Level (UL) for niacin for adults is 35 mg/day, which was based on flushing as the critical adverse effect.


The term niacin refers to nicotinamide (nicotinic acid amide), nicotinic acid (pyridine-3-carboxylic acid), and derivatives that exhibit the biological activity of nicotinamide. The nicotinamide moiety of the pyridine nucleotide coenzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) acts as a hydride ion acceptor or donor in many biological redox reactions. NAD has also been shown to be required for important nonredox adenosine diphosphate (ADP)–ribose transfer reactions involved in deoxyribonucleic acid (DNA) repair and calcium mobilization (Kim et al., 1994; Lautier et al., 1993; Lee et al., 1989). The amino acid tryptophan is converted in part to nicotinamide and thus can contribute to meeting the requirement for niacin.


In the form of the coenzymes NAD and NADP, niacin functions in many biological redox reactions. NAD functions in intracellular respiration and as a codehydrogenase with enzymes involved in the oxidation of fuel molecules such as glyceraldehyde 3-phosphate, lactate, alcohol, 3-hydroxybutyrate, pyruvate, and α-ketoglutarate. NADP functions in reductive biosyntheses such as in fatty acid and steroid syntheses and, like NAD, as a codehydrogenase—as in the oxidation of glucose 6-phosphate to ribose 5-phosphate in the pentose phosphate pathway.

Three classes of enzymes cleave the β-N-glycosylic bond of NAD to free nicotinamide and catalyze the transfer of ADP-ribose in nonredox reactions (Lautier et al., 1993). Two of the three classes catalyze ADP-ribose transfer to proteins: mono-ADP-ribosyltransferases and poly-ADP-ribose polymerase (PARP). The third class promotes the formation of cyclic ADP-ribose, which mobilizes calcium from intracellular stores in many types of cells (Kim et al., 1994).

The enzyme PARP is found in the nuclei of eukaryotic cells and catalyzes the transfer of many ADP-ribose units from NAD to an acceptor protein and also to the enzyme itself. These nuclear poly-ADP-ribose proteins seem to function in DNA replication and repair and in cell differentiation. DNA damage greatly enhances the activity of PARP (Stierum et al., 1994); PARP activity is strongly correlated with cellular apoptosis (Stierum et al., 1994).

Physiology of Absorption, Metabolism, and Excretion

Absorption and Transport

Absorption of nicotinic acid and nicotinamide from the stomach and the intestine is rapid (Bechgaard and Jespersen, 1977) and at low concentrations is mediated by sodium ion-dependent facilitated diffusion. At higher concentrations, passive diffusion predominates, with doses of 3 to 4 g of niacin almost completely absorbed (Bechgaard and Jespersen, 1977). Glycohydrolases in the liver and intestines catalyze the release of nicotinamide from NAD (Henderson and Gross, 1979). Nicotinamide is then transported to tissues to be used in synthesis of NAD when needed. Both forms of the vitamin enter cells by simple diffusion; however, both nicotinic acid and nicotinamide also enter erythrocytes by facilitated transport (Lan and Henderson, 1968).

Metabolism and Excretion

The niacin coenzymes NAD and NADP are synthesized in all tissues of the body from nicotinic acid or nicotinamide. Tissue concentrations of NAD appear to be regulated by the concentration of extracellular nicotinamide, which in turn is under hepatic control and is hormonally influenced. Hydrolysis of hepatic NAD allows the release of nicotinamide for transport to tissues that lack the ability to synthesize the NAD and NADP coenzymes from tryptophan. In the liver some excess plasma nicotinamide is converted to storage NAD (i.e., NAD not bound to enzymes). Tryptophan and nicotinic acid also contribute to storage NAD following the biosynthetic pathway, going through NAMN, which is then reamidated to NAD. In the degradation of NAD, the nicotinamide formed can be reconverted to NAD via nicotinamide ribonucleotide. Nicotinamide can be deamidated in the intestinal tract by intestinal microflora (Bernofsky, 1980).

The body's niacin requirement is met not only by nicotinic acid and nicotinaminde present in the diet, but also by conversion from the dietary protein containing tryptophan. The relative contribution of tryptophan is estimated as follows: 60 mg of tryptophan = 1 mg of niacin = 1 mg of niacin equivalents (Horwitt et al., 1981).

Excess niacin is methylated in the liver to N1-methyl-nicotinamide, which is excreted in the urine along with the 2- and 4-pyridone oxidation products of N1-methyl-nicotinamide. The two major excretion products are N1-methyl-nicotinamide and its pyridone derivative (Mrochek et al., 1976). The proportions differ somewhat depending on the amount and form of niacin ingested and the niacin status of the individual.

Clinical Effects of Inadequate Intake

Pellagra is the classic manifestation of a severe niacin deficiency. It is characterized by a pigmented rash that develops symmetrically in areas exposed to sunlight; changes in the digestive tract that are associated with vomiting, constipation or diarrhea, and a bright red tongue; and neurological symptoms including depression, apathy, headache, fatigue, and loss of memory. Pellagra was common in the United States and parts of Europe in the early twentieth century in areas in which corn or maize (which is low in both niacin and the amino acid tryptophan) was the dietary staple. Although a worldwide problem, pellagra has virtually disappeared from industrialized countries except for its occurrence in chronic alcoholism and in individuals with conditions that disrupt tryptophan pathways. It still appears in India and parts of China and Africa. For example, pellagra was reported in Mozambican refugees in Malawi (Malfait et al., 1993).


Niacin status and dietary requirement can be estimated by using biochemical or clinical endpoints of niacin deficiency. Biochemical changes occur well before the appearance of overt signs of deficiency. Biochemical markers include daily urinary excretion of methylated metabolites, the ratio of 2-pyridone to N1-methyl-nicotinamide in urine, erythrocyte pyridine nucleotides, oral dose uptake tests, erythrocyte nicotinamide adenine dinucleotide (NAD), and plasma 2-pyridone derivative.

Urinary Excretion

The most reliable and sensitive measures of niacin status are urinary excretion of the two major methylated metabolites, N1-methyl-nicotinamide and its 2-pyridone derivative (N1-methyl-2-pyridone-5-carboxamide). Criteria for interpreting urinary N1-methyl-nicotinamide excretion amounts in adults and pregnant women indicate that for adults, 24-hour excretion rates of less than 5.8 μmol/day represent deficient niacin status and 5.8 to 17.5 μmol/day represents low status (Sauberlich et al., 1974). The ratio of the 2-pyridone to N1-methyl-nicotinamide, although independent of age and creatinine excretion, is a measure of protein adequacy rather than niacin status (Shibata and Matsuo, 1989). It is relatively insensitive to a marginal niacin intake of 10 mg/day of niacin equivalents (NEs) and has been shown to be not totally reliable for evaluating an intake of 6 mg/day of NEs (Jacob et al., 1989). The ratio of the 6-pyridone (N1-methyl-nicotinamide-3-carboxamide) to N1-methyl-nicotinamide appears to be associated with the development of clinical symptoms of pellagra, principally dermatitis (Dillon et al., 1992).

Plasma Concentrations

In plasma the 2-pyridone derivative drops below detection limits after a low niacin intake (Jacob et al., 1989). With an oral niacin load (nicotinamide at 20 mg/70 kg body weight), postdose changes in 2-pyridone in both plasma and urine were more responsive to niacin status than changes seen in N1-methyl-nicotinamide. Plasma concentrations of other niacin metabolites and of niacin are not useful markers of niacin status.

Erythrocyte Pyridine Nucleotides

Analysis of erythrocyte NAD concentration promises to be a sensitive indicator of niacin depletion. In an experimental study in which adult male subjects were fed low-niacin diets containing either 6 or 10 mg NE/day, the erythrocyte NAD concentration decreased by 70 percent, whereas the NADP concentration remained unchanged (Fu et al., 1989). An earlier study reported a similar decrease in NAD relative to NADP in fibroblasts grown in niacin-restricted culture (Jacobson et al., 1979). Erythrocyte NAD concentrations provided a marker of niacin depletion equally as sensitive and reliable as excretion of urine metabolites in a study of seven healthy young men (Fu et al., 1989) and in an experimental niacin depletion study of elderly subjects (Ribaya-Mercado et al., 1997).

Transfer of Adenosine Diphosphate Ribose

A possible functional measure for niacin status could be polyadenosine diphosphate (ADP) ribosylation, because ADP ribosylation may contribute to gene stability (poly-ADP-ribose polymerase in the nucleus) and may function in deoxyribonucleic acid (DNA) replication and repair (Stierum et al., 1994). However, the assays have not been developed or refined well enough to be used to judge niacin status at present.


Clinical pellagra may represent various degrees of combined niacin and riboflavin deficiencies (Carpenter and Lewin, 1985). Deficiencies of other micronutrients (e.g., pyridoxine and iron) required to convert tryptophan to niacin may also contribute to the appearance of pellagra. Because pellagra is a late and serious manifestation of deficiency, it was determined that the average requirement must exceed the amount required to prevent pellagra.



Niacin in mature cereal grains is largely bound and thus is only about 30 percent available; alkali treatment of the grain increases the percentage absorbed (Carpenter and Lewin, 1985; Carter and Carpenter, 1982). Niacin in the coenzyme nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NAD/NADP) form in meats appears to be much more available. Niacin added during enrichment or fortification is in the free form and thus highly available. Foods that contain niacin in the free form include beans and liver. Quantitative data are not available on which to base adjustments for the bioavailability from different types of foods.

The conversion efficiency of tryptophan to niacin, although assumed to be 60:1 (Horwitt et al., 1981), varies depending on a number of dietary and metabolic factors. The requirement for preformed niacin is increased by factors that reduce the conversion of tryptophan to niacin (McCormick, 1988), including low tryptophan intake; carcinoid syndrome in which tryptophan is preferentially oxidized to 5-hydroxytryptophan and serotonin; prolonged treatment with the drug Isoniazid, which competes with pyridoxal 5′-phosphate, a vitamin B6–derived coenzyme required in the tryptophan-to-niacin pathway; and Hartnup's disease, an autosomal recessive disorder that interferes with the absorption of tryptophan in the intestine and kidney.

The efficiency of the conversion of dietary tryptophan to niacin is decreased by deficiencies of other nutrients (see “Nutrient-Nutrient Interactions”). Conversion efficiency may increase with some dietary restrictions because of changes in activities of pathway enzymes including tryptophan oxygenase, quinolinate phosphoribosyltransferase, and picolinate carboxylase.

The requirement for preformed niacin as a proportion of the total niacin requirement tends to be lower with higher tryptophan intakes (a greater proportion of tryptophan is available for conversion to NAD once protein synthesis needs are met) and pregnancy (the conversion of tryptophan to niacin is more efficient [Knox, 1951; Rose and Braidman, 1971; Wertz et al., 1958]). Oral contraceptives that contained high doses of estrogen have also been found to increase conversion efficiency (Rose and Braidman, 1971; Wertz et al., 1958). The priority for body tryptophan utilization is protein synthesis before NAD or NADP synthesis.

The 60 to 1 conversion value represents the mean of a wide range of individual values found in human studies that measured the conversion of tryptophan to urinary niacin metabolites (Horwitt et al., 1981). Irrespective of dietary factors, substantial individual differences (30 percent) in the conversion efficiency of tryptophan to niacin have been reported (Horwitt et al., 1981; Patterson et al., 1980).

Nutrient-Nutrient Interactions

Interactions occur between riboflavin and vitamin B6 metabolism in which flavin mononucleotide (FMN) is required for the oxidase that forms coenzymic pyridoxal 5′-phosphate required for conversion of tryptophan to niacin (McCormick, 1989). There is also interdependence of enzymes within the tryptophan-to-niacin pathway where pyridoxal 5′-phosphate, flavin-adenine dinucleotide (FAD), and iron are functional. Hence, inadequate iron, riboflavin, or vitamin B6 status decreases the conversion of tryptophan to niacin. Data are not available to quantitatively assess the effects of these nutrient-nutrient interactions on the niacin requirement.

Energy Intake and Expenditure

No directly relevant studies were found that examined the effect of energy intake or expenditure on the niacin requirement. Examination of individual data from four studies showed no relationship between excretion of N1-methyl-nicotinamide and either energy intake or body weight (Goldsmith et al., 1952, 1956; Horwitt et al., 1956; Jacob et al., 1989). Studies of niacin requirements are consistently presented in relation to energy intake on the basis of the known biochemical function of niacin, as have been past recommendations for niacin intake (NRC, 1989).*

Despite the lack of experimental data, the known biochemical function of niacin in the oxidation of fuel molecules suggests at least a small (10 percent) adjustment to reflect differences in the average energy utilization and size of men and women, a 10 percent increase in the requirement to cover increased energy use during pregnancy, and a small increase in the requirement to account for the efficiency of niacin use in milk production during lactation.


Infants Ages 0 through 12 Months

Method Used to Set the Adequate Intake

As for other nutrients, the Adequate Intake (AI) level for niacin is set for infants based on the observed mean intake of infants fed principally with human milk.

Ages 0 through 6 Months. One study (Ford et al., 1983) of unsupplemented mothers estimated the niacin concentration of their milk at 1.8 mg/L. The adequate intake for niacin for infants ages 0 through 6 months is based on the reported mean volume of milk consumed by this age group (0.78 L/day; see Chapter 2) and the estimate of the niacin concentration in human milk of 1.8 mg/L (0.78 L × 1.8 mg/L = 1.4 mg). The tryptophan content of human milk is approximately 210 mg/L (Committee on Nutrition, 1985). Because of the high rate of protein turnover and net positive nitrogen retention in infancy, it is likely that the standard method for estimating niacin equivalents (NEs) would overestimate the contribution from tryptophan. Thus, the AI for niacin for infants is given in milligrams of preformed niacin only—2 mg/day after rounding up.

Ages 7 through 12 Months. No difference in human milk composition was noted between the first and second 6 months of lactation (Ford et al., 1983). If the reference body weight ratio method described in Chapter 2 to extrapolate from the AI for niacin for infants ages 0 through 6 months is used, the AI for preformed niacin for the older infants is 2 mg/day after rounding. The second method (see Chapter 2), extrapolating from the Estimated Average Requirement (EAR) for adults and adjusting for the expected variance to estimate a recommended intake, gives an AI of 4.1 mg of NEs. A 15 percent coefficient of variation (CV) is used (for discussion, see “Niacin EAR and RDA Summary, Ages 19 Years and Older”). This AI value is expected to be higher than that obtained with the first method because it reflects NEs rather than preformed niacin.

Alternatively, the AI for niacin for infants ages 7 through 12 months can be calculated by using the estimated niacin content of 0.6 L of human milk and the average volume consumed by this age group (niacin content equals 1.1 mg), and adding the amount of niacin provided by solid foods (8 mg), as estimated by Montalto et al. (1985) (see Chapter 2). The result in NEs equals more than 9 mg/day. This value was judged to be unreasonably high because it is more than twice the extrapolated values and because mean intakes of older age groups appear to be much higher than their requirements. Thus the AI for niacin given in NEs is 4 mg/day for infants ages 7 through 12 months—the value extrapolated from estimates of adult requirements.

Niacin AI Summary, Ages 0 through 12 Months

AI for Infants
0–6 months2 mg/day of preformed niacin≈0.2 mg/kg
7–12 months4 mg/day of niacin equivalents≈0.4 mg/kg

Children and Adolescents Ages 1 through 18 Years

Method Used to Estimate the Average Requirement

No data were found on which to base the EAR for niacin for children or adolescents. In the absence of additional information, EARs and RDAs for children and adolescents have been estimated by using the method described in Chapter 2, which extrapolates from adult values.

Niacin EAR and RDA Summary, Ages 1 through 18 years

EAR for Children1–3 years5 mg/day of niacin equivalents
4–8 years6 mg/day of niacin equivalents
EAR for Boys9–13 years9 mg/day of niacin equivalents
14–18 years12 mg/day of niacin equivalents
EAR for Girls9–13 years9 mg/day of niacin equivalents
14–18 years11 mg/day of niacin equivalents

The RDA for niacin is set by using a coefficient of variation (CV) of 15 percent (see Chapter 1 and the discussion of adult requirements that follows) because information is not available on the standard deviation of the requirement for these age groups; the RDA is defined as equal to the EAR plus twice the CV to cover the needs of 97 to 98 percent of the individuals in the group (therefore, for niacin the RDA is 130 percent of the EAR).

RDA for Children1–3 years6 mg/day of niacin equivalents
4–8 years8 mg/day of niacin equivalents
RDA for Boys9–13 years12 mg/day of niacin equivalents
14–18 years16 mg/day of niacin equivalents
RDA for Girls9–13 years12 mg/day of niacin equivalents
14–18 years14 mg/day of niacin equivalents

Adults Ages 19 Years and Older

Method Used to Estimate the Average Requirement

The best biochemical measure for estimating the average requirement was judged to be niacin metabolite excretion data, namely the metabolites N1-methyl-nicotinamide and its 2-pyridone derivative. These measures have been reported the most extensively. The niacin intakes that result in these measures being above the levels considered barely adequate represent some degree of body pool reserve. Niacin metabolites are not excreted until adequate tryptophan is available to meet needs for the synthesis of protein, nicotinamide adenine dinucleotide, and nicotinamide adenine dinucleotide phosphate (Fu et al., 1989; Vivian et al., 1958). Metabolite excretion measures are more sensitive to niacin depletion than are other biochemical measures, such as blood levels of pyridine nucleotides or tryptophan. Whereas pellagra is prevented with NEs of about 11 mg/day (at 2,500 kcal/day), restoration of niacin metabolite excretion beyond minimal occurs at intakes of NEs of about 12 to 16 mg/day. Excretion of N1-methyl-nicotinamide rather than the 2-pyridone derivative is preferred as the target measure for estimating the niacin requirement because this metabolite better differentiates marginal from adequate niacin intakes (Jacob et al., 1989), interpretive guidelines exist for this metabolite (ICNND, 1963), and more data are available for this than for other metabolites.

An average niacin requirement can be estimated as the niacin intake corresponding to an excretion of N1-methyl-nicotinamide that is above the minimal excretion at which pellagra symptoms occur. Urinary excretion of N1-methyl-nicotinamide was found to be 1.2 mg/day in men on low but adequate niacin diets that resulted in no signs or symptoms of pellagra (Horwitt et al., 1956; Jacob et al., 1989). Urinary N1-methyl-nicotinamide excretion was found to be 0.6 mg/day in three females on corn-based, niacin-deficient diets that resulted in clinical signs and symptoms of pellagra (Goldsmith et al., 1952, 1955). A urinary excretion value for N1-methyl-nicotinamide of 1.0 mg/day has been chosen as an interpolated level of niacin excretion; it reflects a niacin intake that is above the intake that results in clinical niacin deficiency and thus is minimal or barely adequate.

Niacin intakes (expressed in NEs) that would correspond to N1-methyl-nicotinamide excretions of 1.0 mg/day are calculated from the results of four experimental studies in which NEs of 8 to 12 mg/day were fed (Table 6-1). A study by Patterson and colleagues (1980) was not used because no individual data were provided. In calculating the niacin intakes that would result in the N1-methyl-nicotinamide excretion level of 1 mg/day, a linear relationship was assumed. This approach is conservative; if more niacin was fed, the ratio of niacin to the excretion of N1-methyl-nicotinamide would become somewhat lower. Because all the studies were judged satisfactory in quality, a weighted average of the results was calculated. The overall average intake equivalent to the excretion of 1 mg/day of N1-methyl-nicotinamide is 11.6 ± 3.94 (standard deviation), with a CV of 34 percent.

TABLE 6-1. Experimental Human Studies of Niacin Intake and Urine N1-methylnicotinamide Excretion.


Experimental Human Studies of Niacin Intake and Urine N1-methylnicotinamide Excretion.

From Table 6-1, it might be interpreted that women require more niacin per 1,000 kcal than do men. However, the studies are too few and not sufficiently comparable to justify such a conclusion, especially considering a lack of evidence that utilization of niacin is less efficient for women than for men. The studies varied widely in methods, including the types of foods provided, which could have marked effects on the bioavailability of niacin. It is thus assumed that women have a slightly lower requirement than do men because of their size and average energy utilization. Therefore, the EAR is estimated to be 12 mg of NEs for men and 11 mg of NEs for women. Data are not available for determining whether the niacin requirement changes with age in adults.

The results of other studies were examined (Goldsmith, 1958; Goldsmith et al., 1956; Horwitt, 1958; Leklem et al., 1975), but coexisting deficiencies, a lack of valid dietary measurements, or both made it necessary to exclude them when deriving the EAR.

Niacin EAR and RDA Summary, Ages 19 Years and Older

On the basis of the data in Table 6-1 and with a minor (approximately 10 percent) decrease for energy in women, the EAR is set at 12 mg/day of NEs for men and 11 mg/day of NEs for women.

EAR for Men19–30 years12 mg/day of niacin equivalents
31–50 years12 mg/day of niacin equivalents
51–70 years12 mg/day of niacin equivalents
> 70 years12 mg/day of niacin equivalents
EAR for Women19–30 years11 mg/day of niacin equivalents
31–50 years11 mg/day of niacin equivalents
51–70 years11 mg/day of niacin equivalents
> 70 years11 mg/day of niacin equivalents

The data in Table 6-1 also suggest a CV of the niacin requirement that is greater than 10 percent. The wide variation in the efficiency of converting tryptophan to niacin may contribute to the large apparent variation. Thus, a CV of 15 percent is used; the RDA is defined as equal to the EAR plus twice the CV to cover the needs of 97 to 98 percent of the individuals in the group (therefore, for niacin the RDA is 130 percent of the EAR).

RDA for Men19–30 years16 mg/day of niacin equivalents
31–50 years16 mg/day of niacin equivalents
51–70 years16 mg/day of niacin equivalents
> 70 years16 mg/day of niacin equivalents
RDA for Women19–30 years14 mg/day of niacin equivalents
31–50 years14 mg/day of niacin equivalents
51–70 years14 mg/day of niacin equivalents
> 70 years14 mg/day of niacin equivalents


Method Used to Estimate the Average Requirement

There is no direct evidence that would suggest a change in the niacin requirement during pregnancy. To derive the EAR for pregnant women, it is estimated that the need for niacin increases by 3 mg/day of NEs to cover increased energy utilization and growth in maternal and fetal compartments, especially during the second and third trimesters.

Niacin EAR and RDA Summary, Pregnancy

By adding 3 mg of NEs to the EAR of 11 mg of NEs for nonpregnant, nonlactating women, the EAR for pregnancy becomes 14 mg of NEs. No adjustment is made for the woman's age.

EAR for Pregnancy
14–18 years14 mg/day of niacin equivalents
19–30 years14 mg/day of niacin equivalents
31–50 years14 mg/day of niacin equivalents

The data in Table 6-1 suggest a CV for the niacin requirement that is greater than 10 percent. The wide variation in the efficiency of converting tryptophan to niacin may contribute to the larger apparent variation. Thus, a CV of 15 percent is used because information is not available on the standard deviation of the requirement for pregnant women; the RDA is defined as equal to the EAR plus twice the CV to cover the needs of 97 to 98 percent of the individuals in the group (therefore, for niacin the RDA is 130 percent of the EAR).

RDA for Pregnancy
14–18 years18 mg/day of niacin equivalents
19–30 years18 mg/day of niacin equivalents
31–50 years18 mg/day of niacin equivalents


Method Used to Estimate the Average Requirement

An estimated 1.4 mg of preformed niacin is secreted daily during lactation. Added to this is a small amount (1 mg) to cover energy expenditure involved in milk production. Thus, the additional amount of niacin needed is 2.4 mg/day of NEs for women who are exclusively breastfeeding an infant.

Niacin EAR and RDA Summary, Lactation

Adding 2.4 mg of NEs to the EAR of 11 mg of NEs for non-pregnant, nonlactating women gives an EAR for niacin for lactation of 13.4 mg, rounded down to 13.

EAR for Lactation
14–18 years13 mg/day of niacin equivalents
19–30 years13 mg/day of niacin equivalents
31–50 years13 mg/day of niacin equivalents

The data in Table 6-1 suggest a CV for the niacin requirement that is greater than 10 percent. The wide variation in the efficiency of converting tryptophan to niacin may contribute to the larger apparent variation. Thus, a CV of 15 percent is used because information is not available on the standard deviation of the requirement during lactation; the RDA is defined as equal to the EAR plus twice the CV to cover the needs of 97 to 98 percent of the individuals in the group (therefore, for niacin the RDA is 130 percent of the EAR).

RDA for Lactation
14–18 years17 mg/day of niacin equivalents
19–30 years17 mg/day of niacin equivalents
31–50 years17 mg/day of niacin equivalents

Special Considerations

The RDAs given above are not expected to be sufficient to meet the needs of persons with Hartnup's disease, liver cirrhosis, or carcinoid syndrome or of those on long-term isoniazid treatment. As for other B vitamins, extra niacin may be required by persons treated with hemodialysis or peritoneal dialysis, those with malabsorption syndrome, pregnant women bearing multiple fetuses, and women breastfeeding more than one infant.


Food Sources

Data obtained from the 1995 Continuing Survey of Food Intakes by Individuals indicate that the greatest contribution to the niacin intake of the U.S. adult population comes from mixed dishes high in meat, fish, or poultry; poultry as an entree; enriched and whole-grain breads and bread products; and fortified ready-to-eat cereals (Table 6-2). In addition to the foods listed in Table 6-2, most flesh foods are sources of niacin, providing at least 2 mg per serving.

TABLE 6-2. Food Groups Providing Niacin in the Diets of U.S. Men and Women Aged 19 Years and Older, CSFII, 1995.


Food Groups Providing Niacin in the Diets of U.S. Men and Women Aged 19 Years and Older, CSFII, 1995.

Dietary Intake

Niacin intake in the United States is generous in comparison with the Estimated Average Requirement (EAR). For example, the median intake by adult women is 17 to 20 mg of niacin (Appendixes G and H) in comparison with an EAR of 11 mg of niacin equivalents (NEs). (Survey data are reported as preformed niacin; no addition has been made for the conversion of tryptophan to niacin.) For all life stage and gender groups it appears that almost all individuals' usual niacin intakes would exceed the EAR if intake was expressed in NEs and thus the contribution of tryptophan was included. Intakes of niacin in two Canadian provinces are reported in NEs and are well above the EAR for all life stage and gender groups (Appendix I).

The Boston Nutritional Status Survey (Appendix F) indicates that this relatively advantaged group of people over age 60 has a median niacin intake of 21 mg/day for men and 17 mg/day for women, again, significantly above the EARs for adult men and women.

Intake from Supplements

Information from the Boston Nutritional Status Survey on the use of niacin supplements by a free-living elderly population is given in Appendix F. For those taking supplements, the fiftieth percentile of supplemental niacin intake was 20 mg for men and 30 mg for women. In the 1986 National Health Interview Survey, 26 percent of all adults reported use of supplements containing niacin (Moss et al., 1989). Supplements containing up to about 400 mg of niacin are available without a prescription.


Hazard Identification

Adverse Effects

There is no evidence of adverse effects from the consumption of naturally occurring niacin in foods. Therefore, this review is limited to evidence concerning intake of niacin as a supplement, food fortificant, or pharmacological agent.

One report showed adverse effects after consumption of bagels to which 60 times the normal amount of niacin had been added inadvertently (CDC, 1983). Most of the data on the adverse effects of excess niacin intake are from studies and case reports involving patients with hyperlipidemia or other disorders who were treated with pharmacological preparations containing immediate-release nicotinic acid or slow- or sustained-release nicotinic acid. The Tolerable Upper Intake Level (UL) developed here applies to all forms of niacin added to foods or taken as supplements (e.g., immediate-release, slow or sustained-release nicotinic acid, and niacinamide [nicotinamide]). Adverse effects such as nausea, vomiting, and signs and symptoms of liver toxicity have been observed at nicotinamide intakes of 3,000 mg/day (Rader et al., 1992) compared with intakes of nicotinic acid of 1,500 mg/day (McKenney et al., 1994). The generic term niacin may be considered interchangeable with nicotinic acid. As described below, the critical adverse effect selected was flushing to the extent that it results in a change in the dosing pattern or withdrawal from treatment.

Vasodilatory Effects (Flushing). The term flushing covers a burning, tingling, and itching sensation as well as a reddened flush primarily on the face, arms, and chest. Flushing occurs in many patients treated with nicotinic acid therapeutically. It is often accompanied by pruritus, headaches, and increased intracranial blood flow (Miller and Hayes, 1982). Occasionally, it is accompanied by pain (Bean and Spies, 1940). Case reports and clinical trials have reported flushing effects at oral doses of 30 to 1,000 mg/day within 30 minutes to 6 weeks of the initial dose (CDC, 1983; Estep et al., 1977; Henkin et al., 1990; McKenney et al., 1994; Sebrell and Butler, 1938; Spies et al., 1938). Although flushing is a transient effect, it often results in patients deciding to withdraw from treatment.

In a study of the flushing effects of nicotinic acid and other pyridine compounds in humans, Bean and Spies (1940) suggest that pyridine compounds without a carboxyl radical in the 3 position of the pyridine ring do not produce flushing effects. Nicotinamide, which does not have a carboxyl radical in the 3 position, does not appear to be associated with flushing.

Flushing appears to be more closely related to a continuous rise in plasma nicotinic acid concentrations than to the absolute dose. Tolerance to nicotinic acid-induced flushing can develop whereby the effects are minimized when the dose is slowly increased over time (Stern et al., 1991). Flushing effects can also be reduced somewhat by taking niacin with food (Knodel and Talbert, 1987). Flushing has been shown to be prostaglandin mediated, and tolerance results from reduction in prostaglandin levels with continued administration (Morrow et al., 1989, 1992).

Gastrointestinal Effects. In addition to flushing, nonspecific gastrointestinal effects are common in patients treated with nicotinic acid (Knodel and Talbert, 1987), especially with slow-release preparations (McKenney et al., 1994; Rader et al., 1992). The gastrointestinal effects in patients taking the slow-release form have been shown to be associated with liver enzyme elevations (Gibbons et al., 1995).

Hepatotoxicity. The hepatotoxicity of niacin has been demonstrated in numerous case reports (Clementz and Holmes, 1987; Dalton and Berry, 1992; Einstein et al., 1975; Etchason et al., 1991; Ferenchick and Rovner, 1989; Frost, 1991; Goldstein, 1988; Henkin et al., 1990; Hodis, 1990; Knapp and Middleton, 1991; Knopp, 1991; McKenney et al., 1994; Mullin et al., 1989; Palumbo, 1991; Patterson et al., 1983). In the most severe cases, patients develop liver dysfunction and fulminant hepatitis and may progress to stage 3 and 4 encephalopathy requiring liver transplantation (Clementz and Holmes, 1987; Hodis, 1990; Mullin et al., 1989). The most frequently observed manifestations of niacin-induced hepatitis are jaundice and increased levels of serum transaminases (Etchason et al., 1991). These effects are typically associated with high doses (3 to 9 g/day of niacin) used to treat patients with hypercholesterolemia for periods of months to years (Clementz and Holmes, 1987; Einstein et al., 1975; Pardue, 1961; Patterson et al., 1983; Rivin, 1959; Winter and Boyer, 1973). Almost all of the patients in these case reports were taking the slow-release form. A recent double-blind comparison study suggested that the slow-release form is more hepatotoxic than the immediate-release form (McKenney et al., 1994). However, another study reported hepatotoxicity with both forms of niacin (Gray et al., 1994).

Glucose Intolerance. Large doses (3 g/day) of nicotinic acid used to treat patients with hypercholesterolemia have produced impaired glucose tolerance in otherwise apparently healthy individuals (Miettinen et al., 1969). The adverse effects on glucose tolerance have been observed during short- and long-term administration of the drug (Schwartz, 1993).

Ocular Effects. Niacin treatment may produce significant ocular effects, including blurred vision, toxic amblyopia, macular edema, and cystic maculopathy. However, there are very few cases in the literature (Fraunfelder et al., 1995). Doses of 1.5 to 5 g/day of niacin have been associated with ocular effects (Fraunfelder et al., 1995; Gass, 1973; Millay et al., 1988). Niacin-induced ocular effects appear to be reversible and dose dependent.


Flushing is the adverse effect first observed after excess niacin intake and is generally observed at lower doses than are other effects. Flushing that results in patients deciding to change the pattern of niacin intake (i.e., reduce the amount taken at a time or withdraw from treatment) was selected as the most appropriate endpoint on which to base a UL. Although nicotinamide appears not to be associated with flushing effects, a UL for nicotinic acid that is based on flushing is considered protective against potential adverse effects of nicotinamide. The data on hepatotoxicity are considered less relevant to the general population because they involve large doses taken for long periods of time for the treatment of a medical condition.

Dose-Response Assessment


Data Selection. The data sets used to identify the lowest-observed-adverse-effect level (LOAEL) for niacin included anecdotal reports and clinical trials involving oral intake of niacin by healthy individuals. Studies involving parenteral administration were not considered in the dose-response assessment. Studies involving immediate-release forms of niacin were considered more relevant to niacin intake by the general population than were studies involving sustained-release forms.

Identification of a LOAEL. The data are not adequate to identify a no-observed-adverse-effect level (NOAEL) for flushing. To identify a LOAEL, flushing reactions were considered if they resulted in a patient either changing the form or amount of niacin used or withdrawing from treatment. A LOAEL of 50 mg/day was identified based on a study by Sebrell and Butler (1938) in which four (66 percent) of six persons experienced a flushing sensation after oral intake of 50 mg/day of nicotinic acid given with meals for 92 days. In one of the four subjects who experienced flushing effects, the daily dose of 50 mg was given as 25 mg in the morning and evening. Although this study also reported a flushing reaction in one of six subjects taking 30 mg of nicotinic acid daily on day 32 of intake, this reaction was not bothersome enough to change the dosing pattern. Sebrell and Butler (1938) was selected as the critical study for identifying a LOAEL and deriving a UL because it provides the lowest effect level. A study by Spies et al. (1938) provides supportive evidence for a LOAEL of 50 mg/day. In this study, five of 100 individuals (5 percent) experienced flushing after a single oral dose of 50 mg of nicotinic acid, 50 individuals (50 percent) experienced flushing after 100 mg, and all individuals experienced flushing after 500 mg.

There is one case report showing that 14 of 69 persons (20 percent) experienced onset of rash, pruritus, and a sensation of warmth about 30 minutes after consuming one or more pumpernickel bagels to which niacin had been inadvertently added from an improperly labeled container (CDC, 1983). The bagels were found to contain an average of 190 mg of niacin.

Uncertainty Assessment. Because of the transient nature of the flushing effect, a small uncertainty factor (UF) of 1.5 was selected. A smaller UF was not appropriate because it is applied to a LOAEL rather than a NOAEL.

Derivation of a UL. A LOAEL of 50 mg/day was divided by a UF of 1.5 to obtain the UL for adults of 35 mg/day, a rounded estimate.

UL for Adults19 years and older35 mg/day of niacin

Other Life Stage Groups

For infants the UL was judged not determinable because of a lack of data on adverse effects in this age group and concern about the infant's ability to handle excess amounts. To prevent high levels of intake, the only source of intake for infants should be from food. No data were found to suggest that other life stage groups have increased susceptibility to flushing effects from excess niacin intake. Therefore, the UL of 35 mg/day is also set for pregnant and lactating adult women. The UL of 35 mg/day for adults was adjusted for children and adolescents on the basis of relative body weight as described in Chapter 3 and by using reference weights from Chapter 1, Table 1-2. Values have been rounded down.

UL for Infants
0–12 monthsNot possible to establish; source of intake should be formula and food only
UL for Children
1–3 years10 mg/day of niacin
4–8 years15 mg/day of niacin
9–13 years20 mg/day of niacin
UL for Adolescents
14–18 years30 mg/day of niacin
UL for Pregnancy
14–18 years30 mg/day of niacin
19 years and older35 mg/day of niacin
UL for Lactation
14–18 years30 mg/day of niacin
19 years and older35 mg/day of niacin

Special Considerations

A review of the literature identified individuals with the following conditions as being distinctly susceptible to the adverse effects of excess niacin intake: hepatic dysfunction or a history of liver disease, diabetes mellitus, active peptic ulcer disease, gout, cardiac arrhythmias, inflammatory bowel disease, migraine headaches, and alcoholism. Therefore, people with these conditions may not be protected by the UL for niacin for the general population.

Intake Assessment

On the basis of data from the Third National Health and Nutrition Survey, the highest mean intake of niacin from diet and supplements for any life stage and gender group was 39 mg/day. This intake was being consumed by men aged 31 through 50 years, women over age 70, and pregnant women aged 14 through 55 years. The highest reported intake at the ninety-fifth percentile was 77 mg/day in women aged 51 through 70 years (see Appendix H). Niacin is available over the counter in dosages ranging up to 100 mg or more (in the immediate-release form).

Risk Characterization

Niacin intake data indicate that a small percentage of the U.S. population is likely to exceed the UL. Individuals who take over-the-counter niacin to treat themselves, for example, for high blood cholesterol, might exceed the UL on a chronic basis. The UL is not meant to apply to individuals who are receiving niacin under medical supervision.


Data useful for setting the Estimated Average Requirement (EAR) for children, adolescents, pregnant women, and lactating women are scanty, but evidence suggests that niacin intake in the United States and Canada is generous relative to need. Priority should be given to studies in two areas:

  • the niacin requirement to satisfy nicotinamide adenine dinucleotide (NAD) needs for increased adenosine diphosphate ribosylation resulting from oxidant-deoxyribonucleic acid damage and
  • sensitive and specific blood measures of niacin status. Current assessments of niacin status and requirement are based solely on urinary metabolite measures; measurements of plasma metabolites such as the 2-pyridone derivatives may be productive. Two recent experimental studies have suggested erythrocyte NAD as a functional blood measure of niacin status (Fu et al., 1989; Ribaya-Mercado et al., 1997), but further work is needed in clinical populations.


  • Bean WB, Spies TD. A study of the effects of nicotinic acid and related pyridine and pyrazine compounds on the temperature of the skin of human beings. Am Heart J. 1940;20:62–75.
  • Bechgaard H, Jespersen S. GI absorption of niacin in humans. J Pharm Sci. 1977;66:871–872. [PubMed: 874791]
  • Bernofsky C. Physiology aspects of pyridine nucleotide regulation in mammals. Mol Cell Biochem. 1980;33:135–143. [PubMed: 6450878]
  • Carpenter KJ, Lewin WJ. A reexamination of the composition of diets associated with pellagra. J Nutr. 1985;115:543–552. [PubMed: 3998856]
  • Carter EG, Carpenter KJ. The bioavailability for humans of bound niacin from wheat bran. Am J Clin Nutr. 1982;36:855–861. [PubMed: 6215855]
  • CDC (Centers for Disease Control and Prevention). Niacin intoxication from pumpernickel bagels—New York. MMWR. 1983;32:305. [PubMed: 6406817]
  • Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol. 1987;9:582–584. [PubMed: 3680913]
  • Committee on Nutrition. Pediatric Nutrition Handbook. 2nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1985. Composition of human milk: Normative data; pp. 363–368.
  • Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992;93:102–104. [PubMed: 1626557]
  • Dillon JC, Malfait P, Demaux G, Foldihope C. Urinary metabolites of niacin during the course of pellagra. Ann Nutr Metab. 1992;36:181–185. [PubMed: 1471854]
  • Einstein N, Baker A, Galper J, Wolfe H. Jaundice due to nicotinic acid therapy. Am J Dig Dis. 1975;20:282–286. [PubMed: 1124751]
  • Estep DL, Gay GR, Rappolt RT Sr. Preliminary report of the effects of propranolol HCl on the discomfiture caused by niacin. Clin Toxicol. 1977;11:325–328. [PubMed: 334454]
  • Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Marttila JK, Kottke BA. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991;66:23–28. [PubMed: 1988755]
  • Ferenchick G, Rovner D. Case report: Hepatitis and hematemesis complicating nicotinic acid use. Am J Med Sci. 1989;298:191–193. [PubMed: 2801756]
  • Ford JE, Zechalko A, Murphy J, Brooke OG. Comparison of the B vitamin composition of milk from mothers of preterm and term babies. Arch Dis Child. 1983;58:367–372. [PMC free article: PMC1627853] [PubMed: 6859917]
  • Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79:54–56. [PMC free article: PMC505021] [PubMed: 7880795]
  • Frost PH. All niacin is not the same. Ann Intern Med. 1991;114:1065. [PubMed: 2029108]
  • Fu CS, Swendseid ME, Jacob RA, McKee RW. Biochemical markers for assessment of niacin status in young men: Levels of erythrocyte niacin coenzymes and plasma tryptophan. J Nutr. 1989;119:1949–1955. [PubMed: 2621487]
  • Gass JD. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76:500–510. [PubMed: 4743805]
  • Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 1995;99:378–385. [PubMed: 7573093]
  • Goldsmith GA. Niacin-tryptophan relationships in man and niacin requirement. Am J Clin Nutr. 1958;6:479–486. [PubMed: 13594872]
  • Goldsmith GA, Sarett HP, Register UD, Gibbens J. Studies on niacin requirement in man. 1. Experimental pellagra in subjects on corn diets low in niacin and tryptophan. J Clin Invest. 1952;31:533–542. [PMC free article: PMC436449] [PubMed: 14938430]
  • Goldsmith GA, Rosenthal HL, Gibbens J, Unglaub WG. Studies on niacin requirement in man. 2. Requirement on wheat and corn diets low in tryptophan. J Nutr. 1955;56:371–386. [PubMed: 13243149]
  • Goldsmith GA, Gibbens J, Unglaub WG, Miller ON. Studies on niacin requirement in man. 3. Comparative effects of diets containing lime-treated and untreated corn in the production of experimental pellagra. Am J Clin Nutr. 1956;4:151–160. [PubMed: 13302163]
  • Goldstein MR. Potential problems with the widespread use of niacin. Am J Med. 1988;85:881. [PubMed: 3195612]
  • Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121:252–258. [PubMed: 7741833]
  • Henderson LM, Gross CJ. Metabolism of niacin and niacinamide in perfused rat intestine. J Nutr. 1979;109:654–662. [PubMed: 34678]
  • Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. J Am Med Assoc. 1990;264:241–243. [PubMed: 2355446]
  • Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. J Am Med Assoc. 1990;264:181. [PubMed: 2355439]
  • Horwitt MK. Niacin-tryptophan requirements of man. J Am Diet Assoc. 1958;34:914–919. [PubMed: 13575093]
  • Horwitt MK, Harvey CC, Rothwell WS, Cutler JL, Haffron D. Tryptophanniacin relationships in man: Studies with diets deficient in riboflavin and niacin, together with observations on the excretion of nitrogen and niacin metabolites. J Nutr. 1956;60:1–43.
  • Horwitt MK, Harper AE, Henderson LM. Niacin-tryptophan relationships for evaluating niacin equivalents. Am J Clin Nutr. 1981;34:423–427. [PubMed: 6452053]
  • ICNND (Interdepartmental Committee on Nutrition for National Defense). Manual for Nutrition Surveys. 2nd ed. Bethesda, MD: National Institutes of Health; 1963. p. 244.
  • Jacob RA, Swendseid ME, McKee RW, Fu CS, Clemens RA. Biochemical markers for assessment of niacin status in young men: Urinary and blood levels of niacin metabolites. J Nutr. 1989;119:591–598. [PubMed: 2522982]
  • Jacobson EL, Lange RA, Jacobson MK. Pyridine nucleotide synthesis in 3T3 cells. J Cell Physiol. 1979;99:417–425. [PubMed: 37252]
  • Kim H, Jacobson EL, Jacobson MK. NAD glycohydrolases: A possible function in calcium homeostasis. Mol Cell Biochem. 1994;138:237–243. [PubMed: 7898469]
  • Knapp TR, Middleton RK. Adverse effects of sustained-release niacin. Ann Pharmacother. 1991;25:253–254. [PubMed: 2028632]
  • Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2:10–32. [PubMed: 3547004]
  • Knopp RH. Niacin and hepatic failure. Ann Intern Med. 1991;111:769. [PubMed: 2802441]
  • Knox WE. Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: Specific enzyme adaptation and stimulation of the pituitaryadrenal system. Br J Exp Pathol. 1951;32:462–469. [PMC free article: PMC2073205] [PubMed: 14886511]
  • Lan SJ, Henderson LM. Uptake of nicotinic acid and nicotinamide by rat erythrocytes. J Biol Chem. 1968;243:3388–3394. [PubMed: 4231915]
  • Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem. 1993;122:171–193. [PubMed: 8232248]
  • Lee HC, Walseth TF, Bratt GT, Hayes RN, Clapper DL. Structural determination of a cyclic metabolite of NAD+ with intracellular CA2+-mobilizing activity. J Biol Chem. 1989;264:1608–1615. [PubMed: 2912976]
  • Leklem JE, Brown RR, Rose DP, Linkswiler H, Arend RA. Metabolism of tryptophan and niacin in oral contraceptive users receiving controlled intakes of vitamin B6. Am J Clin Nutr. 1975;28:146–156. [PubMed: 1115024]
  • Malfait P, Moren A, Dillon JC, Brodel A, Begkoyian G, Etchegorry MG, Malenga G, Hakewill P. An outbreak of pellagra related to changes in dietary niacin among Mozambican refugees in Malawi. Int J Epidemiol. 1993;22:504–511. [PubMed: 8359968]
  • McCormick DB. Niacin. In: Shils ME, Young VR, editors. Modern Nutrition in Health and Disease. Philadelphia: Lea & Febiger; 1988. pp. 370–375.
  • McCormick DB. Two interconnected B vitamins: Riboflavin and pyridoxine. Physiol Rev. 1989;69:1170–1198. [PubMed: 2678166]
  • McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc. 1994;271:672–677. [PubMed: 8309029]
  • Miettinen TA, Taskinen MR, Pelkonen R, Nikkila EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand. 1969;186:247–253. [PubMed: 5378103]
  • Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology. 1988;95:930–936. [PubMed: 3174043]
  • Miller DR, Hayes KC. Vitamin excess and toxicity. In: Hathcock JN, editor. Nutritional Toxicology. Vol. 1. New York: Academic Press; 1982. pp. 81–133.
  • Montalto MB, Benson JD, Martinez GA. Nutrient intake of formula-fed infants and infants fed cow's milk. Pediatrics. 1985;75:343–351. [PubMed: 3969338]
  • Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263–274. [PubMed: 2475889]
  • Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98:812–815. [PubMed: 1373750]
  • Moss AJ, Levy AS, Kim I, Park YK. Use of Vitamin and Mineral Supplements in the United States: Current Users, Types of Products, and Nutrients. Hyattsville, MD: National Center for Health Statistics; 1989. Advance Data, Vital and Health Statistics of the National Center for Health Statistics, No. 174.
  • Mrochek JE, Jolley RL, Young DS, Turner WJ. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem. 1976;22:1821–1827. [PubMed: 135660]
  • Mullin GE, Greenson JK, Mitchel MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. 1989;111:253–255. [PubMed: 2665592]
  • NRC (National Research Council). Recommended Dietary Allowances. 10th ed. Washington, DC: National Academy Press; 1989.
  • Palumbo PJ. Rediscovery of crystalline niacin. Mayo Clin Proc. 1991;66:112–113. [PubMed: 1988752]
  • Pardue WO. Severe liver dysfunction during nicotinic acid therapy. J Am Med Assoc. 1961;175:137–138. [PubMed: 13732750]
  • Patterson JI, Brown RR, Linkswiler H, Harper AE. Excretion of tryptophanniacin metabolites by young men: Effects of tryptophan, leucine, and vitamin B6 intakes. Am J Clin Nutr. 1980;33:2157–2167. [PubMed: 6448542]
  • Patterson DJ, Dew EW, Gyorkey R, Graham GY. Niacin hepatitis. South Med J. 1983;76:239–241. [PubMed: 6823602]
  • Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77–81. [PubMed: 1731514]
  • Ribaya-Mercado JD, Russell RM, Rasmussen HM, Crim MC, Perrone-Petty G, Gershoff SN. Effect of niacin status on gastrointestinal function and serum lipids. FASEB J. 1997;11:A179.
  • Rivin AU. Jaundice occurring during nicotinic acid therapy for hypercholesteremia. J Am Med Assoc. 1959;170:2088–2089. [PubMed: 13672808]
  • Rose DP, Braidman IP. Excretion of tryptophan metabolites as affected by pregnancy, contraceptive steroids, and steroid hormones. Am J Clin Nutr. 1971;24:673–683. [PubMed: 4325646]
  • Sauberlich HE, Skala JH, Dowdy RP. Laboratory Tests for the Assessment of Nutritional Status. Boca Raton, FL: CRC Press; 1974. [PubMed: 4217238]
  • Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med. 1993;153:2050–2052. [PubMed: 8357290]
  • Sebrell WH, Butler RE. A reaction to the oral administration of nicotinic acid. J Am Med Assoc. 1938;111:2286–2287.
  • Shibata K, Matsuo H. Effect of supplementing low protein diets with the limiting amino acids on the excretion of N1-methylnicotinamide and its pyridones in rats. J Nutr. 1989;119:896–901. [PubMed: 2526206]
  • Spies TD, Bean WB, Stone RE. The treatment of subclinical and classic pellagra. J Am Med Assoc. 1938;111:584–592.
  • Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50:66–70. [PubMed: 1855354]
  • Stierum RH, Vanherwijnen MH, Hageman GJ, Kleinjans JC. Increased poly (ADP-ribose) polymerase activity during repair of (+/-)-anti-benzo[a]pyrene diolepoxide-induced DNA damage in human peripheral blood lymphocytes in vitro. Carcinogenesis. 1994;15:745–751. [PubMed: 8149490]
  • Vivian VM, Chaloupka MM, Reynolds MS. Some aspects of tryptophan metabolism in human subjects. 1. Nitrogen balances, blood pyridine nucleotides, and urinary excretion of N-methylnicotinamide and N-methyl-2-pyridone-5-carboxamide on a low-niacin diet. J Nutr. 1958;66:587–598. [PubMed: 13621283]
  • Wertz AW, Lojkin ME, Bouchard BS, Derby MB. Tryptophan-niacin relationships in pregnancy. J Nutr. 1958;64:339–353. [PubMed: 13526016]
  • Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med. 1973;289:1180–1182. [PubMed: 4271091]



It is recognized that studies of individuals in forced starvation situations have reported that individuals with the greatest initial body weights (and thus the greatest energy expenditure) developed signs of deficiency more rapidly than did others consuming similar diets but who weighed less initially. However, the panel could not quantify this difference as assessed by changes in available indicators of adequacy by those consuming typical diets in Canada and the United States.

Copyright © 1998, National Academy of Sciences.
Bookshelf ID: NBK114304


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.6M)
  • Disable Glossary Links

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...